The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

In memory of Akakia Shotovicha Gamkrelidze

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(1): 114‑114

Read: 1107 times

Contact the author
Table of contents

IN MEMORY OF AKAKIA SHOTOVICHA GAMKRELIDZE
IN MEMORY OF AKAKIA SHOTOVICHA GAMKRELIDZE

To cite this article:

In memory of Akakia Shotovicha Gamkrelidze. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(1):114‑114. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The objective was to study efficacy and safety of ceraxon (citicoline) used perorally in dose 1000 mg daily in the treatment of cognitive disturbances in patients with amnesic type of mild cognitive impairment (MCI). Twenty patients, aged from 50 to 90 years, received ceraxon in dose 1000 mg twice a day during 90 days. The state of patients was assessed with a battery of scales and tests with the following statistical data analysis. The significant results on the clinical effect of the drug on cognitive disturbances and good tolerability of ceraxon have been obtained. The authors recommend ceraxon for long-term preventive treatment in high risk populations for Alzheimer's disease.

Close metadata

References:

  1. Amcheslavskii V.G. Osobennosti monitoringa i intensivnoi terapii kriticheskikh sostoyanii pri ostrykh tserebral'nykh povrezhdeniyakh. Zhurn nevrol i psikhiat 2009; 109; 7: 48-61.
  2. Gavrilova S.I. Farmakoterapiya bolezni Al'tsgeimera. M: Pul's 2007; 94-109.
  3. Gavrilova S.I., Fedorova Ya.B., Roshchina I.F., Korovaitseva G.I. Prognoz myagkogo kognitivnogo snizheniya (Mild cognitive impairment) po dannym dvukhletnego kliniko katamnesticheskogo issledovaniya. Zhurn nevrol i psikhiat 2007; 107: 1: 4-10.
  4. Gavrilova S.I., Kolykhalov I.V., Fedorova Ya.B. i dr. Vozmozhnosti preventivnoi terapii bolezni Al'tsgeimera: rezul'taty 3-letnego prospektivnogo otkrytogo sravnitel'nogo issledovaniya effektivnosti i bezopasnosti kursovoi terapii tserebrolizinom i kavintonom u pozhilykh patsientov s sindromom myagkogo kognitivnogo snizheniya. Zhurn nevrol i psikhiat 2010; 110: 1: 68-75.
  5. Fedorova Ya.B. Sindrom myagkogo kognitivnogo snizheniya (obzor literatury). Psikhiatriya 2007; 6: 45-55.
  6. Adibhatla R.M., Hatcher J.F., Dempsey R.J. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 2002; 80: 1: 12-23.
  7. Adibhatla R.M., Hatcher J.F. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res 2003; 73: 308-315.
  8. Alvarez X.A., Sampedro C., Lozano R., Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods Find Exp Clin Pharmacol 1999; 21: 535-540.
  9. Agnoli A., Bruno G., Fioravanti M. et al. Therapeutic approach to senile memory impairment: a double-blind clinical trial with CDP choline. In: Alzheimer's Disease: Proceedings of the Fifth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Eds. R. Wurtman, S. Corkin, J. Growden, Boston, MA: Birkhauser 1989; 649-654.
  10. Braak H., Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991; 1: 213-216.
  11. Braak H., Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 1996; 165: 3-12.
  12. Caamaoo J., Gomez M.J., Franco A., Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol 1994; 16: 211-218.
  13. Cacabelos R., Alvarez X.A., Franco-Maside A. et al. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia. Ann N Y Acad Sci 1993; 695: 321-323.
  14. Cacabelos R., Caamaoo J., Gomez M.J. et al. Therapeutic effects of CDP-choline in Alzheimer's disease. Ann N Y Acad Sci 1996; 777: 399-403.
  15. Cho H.J., Kim Y.J. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol 2009; 31: 3: 171-176.
  16. Clark W.M., Warach S.J., Pettigrew L.C. et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997; 49: 671-678.
  17. Clark W.M., Williams B.J., Selzer K.A. et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999; 30: 2592-2597.
  18. Clark W.M., Wechsler L.R., Sabounjian L.A., Schwiderski U.E. Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001; 57: 1595-1602.
  19. Conant R., Schauss A.G. Terapevticheskoe primenenie tsitikolina pri insul'te i kognitivnykh disfunktsiyakh u pozhilykh patsientov. Consilium medicum 2008; 7: 81-88.
  20. D'Orlando K.J., Sandage B.W.Jr. Citicolone (CDP-choline): mechanisms of action and effects in ischemic brain injuri. Neurol Res 1995; 17: 281-284.
  21. Dubois B., Albert M.L. Amnestic MCI or prodromal Alzheimer's disease. Lancet Neurology 2004; 3: 246-248.
  22. Duff-Canning S.J., L., Stuss D. et al. Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia Neurology 2004; 62: 4: 556-562.
  23. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Research 1975; 2: 189-198.
  24. Golomb J., Kluger A., Garrard P., Ferris S. Clinician's Manuel on Mild Cognitive Impairment. Science. London 2001; 56.
  25. Jones S., Laukka E.J., Bäckman L. Differential verbal fluency deficits in the preclinical stages of Alzheimer's disease and vascular dementia. Cortex 2006; 42: 3: 347-355.
  26. Lopez-Coviella I., Agut J., Savci V. et al. Evidence that 5'-cytidinediphosphocholine can affect brain phospholipids composition by increasing choline and cytidine plasma levels. J Neurochem 1995; 65: 889-894.
  27. Morris J.C. The clinical dementia rating (CDR). Current version and scoring rules. Neurology 1993; 43: 2412-2414.
  28. Nitta A., Itoh A., Hasegawa T., Nabeshima T. Betaamyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 1994; 170: 63-66.
  29. Nitta A., Fukuta T., Hasegawa T., Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 1997; 73: 51-57.
  30. Petersen R.C., Smith G.E., Waring S.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
  31. Petkov V.D., Kehayov R.A. et al. Effects of citidine diphosphate choline on rats with memory deficits. Arzneimittelforschung 1993; 43: 822-828.
  32. Plataras C., Tsakiris S., Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na(+), K(+)-ATPase in adult rats. Clin Biochem 2000; 33: 351-357.
  33. Rao A.M., Hatcher J.F., Dempsey R.J. Does DPcholine modulate phospholipase activities after transient forebrain ischemia? Brain Res 2001; 893: 268-272; 19.
  34. Reisberg B., Ferris S.H., de Leon M.J. et al. The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139.
  35. Secades J.J., Lorenzo J.L. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006; Suppl B: 1-56.
  36. Spiers P.A., Myers D., Hochanadel G.S. et al. Citicoline improves verbal memory in aging. Arch Neurol 1996; 53: 441-448.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.